248 related articles for article (PubMed ID: 22584647)
1. The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis.
Smith T; Jordaens L; Theuns DA; van Dessel PF; Wilde AA; Hunink MG
Eur Heart J; 2013 Jan; 34(3):211-9. PubMed ID: 22584647
[TBL] [Abstract][Full Text] [Related]
2. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population.
Cowie MR; Marshall D; Drummond M; Ferko N; Maschio M; Ekman M; de Roy L; Heidbuchel H; Verboven Y; Braunschweig F; Linde C; Boriani G
Europace; 2009 Jun; 11(6):716-26. PubMed ID: 19359333
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of implantable cardioverter-defibrillators.
Sanders GD; Hlatky MA; Owens DK
N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population.
Chan PS; Stein K; Chow T; Fendrick M; Bigger JT; Vijan S
J Am Coll Cardiol; 2006 Jul; 48(1):112-21. PubMed ID: 16814657
[TBL] [Abstract][Full Text] [Related]
5. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction).
Linde C; Mealing S; Hawkins N; Eaton J; Brown B; Daubert JC;
Eur Heart J; 2011 Jul; 32(13):1631-9. PubMed ID: 21112898
[TBL] [Abstract][Full Text] [Related]
7. Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: a cost-effectiveness study.
Filion KB; Xie X; van der Avoort CJ; Dendukuri N; Brophy JM
Int J Technol Assess Health Care; 2009 Apr; 25(2):151-60. PubMed ID: 19331707
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry.
Thijssen J; van den Akker van Marle ME; Borleffs CJ; van Rees JB; de Bie MK; van der Velde ET; van Erven L; Schalij MJ
Pacing Clin Electrophysiol; 2014 Jan; 37(1):25-34. PubMed ID: 23998638
[TBL] [Abstract][Full Text] [Related]
9. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
[TBL] [Abstract][Full Text] [Related]
10. Is combined resynchronisation and implantable defibrillator therapy a cost-effective option for left ventricular dysfunction?
Bond M; Mealing S; Anderson R; Dean J; Stein K; Taylor RS
Int J Cardiol; 2009 Nov; 137(3):206-15. PubMed ID: 18703244
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age.
Sanders GD; Kong MH; Al-Khatib SM; Peterson ED
Am Heart J; 2010 Jul; 160(1):122-31. PubMed ID: 20598982
[TBL] [Abstract][Full Text] [Related]
12. Potential cost-effectiveness of prophylactic use of the implantable cardioverter defibrillator or amiodarone after myocardial infarction.
Sanders GD; Hlatky MA; Every NR; McDonald KM; Heidenreich PA; Parsons LS; Owens DK
Ann Intern Med; 2001 Nov; 135(10):870-83. PubMed ID: 11712877
[TBL] [Abstract][Full Text] [Related]
13. Impact of age and medical comorbidity on the effectiveness of implantable cardioverter-defibrillators for primary prevention.
Chan PS; Nallamothu BK; Spertus JA; Masoudi FA; Bartone C; Kereiakes DJ; Chow T
Circ Cardiovasc Qual Outcomes; 2009 Jan; 2(1):16-24. PubMed ID: 20031808
[TBL] [Abstract][Full Text] [Related]
14. Life expectancy gains and cost-effectiveness of implantable cardioverter/defibrillators for the primary prevention of sudden cardiac death in patients with hypertrophic cardiomyopathy.
You JJ; Woo A; Ko DT; Cameron DA; Mihailovic A; Krahn M
Am Heart J; 2007 Nov; 154(5):899-907. PubMed ID: 17967596
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function.
Schaer BA; Ammann P; Sticherling C; Zellweger MJ; Cron TA; Osswald S
Int J Cardiol; 2006 Mar; 108(1):26-30. PubMed ID: 16516695
[TBL] [Abstract][Full Text] [Related]
16. Factors predisposing to ventricular tachyarrhythmia leading to appropriate ICD intervention in patients with coronary artery disease or non-ischaemic dilated cardiomyopathy.
Lelakowski J; Piekarz J; Rydlewska A; Majewski J; Senderek T; Ząbek A; Małecka B
Kardiol Pol; 2012; 70(12):1264-75. PubMed ID: 23264245
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
[TBL] [Abstract][Full Text] [Related]
18. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation.
Colquitt JL; Mendes D; Clegg AJ; Harris P; Cooper K; Picot J; Bryant J
Health Technol Assess; 2014 Aug; 18(56):1-560. PubMed ID: 25169727
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of implantable cardioverter-defibrillators in Brazil: primary prevention analysis in the public sector.
Ribeiro RA; Stella SF; Camey SA; Zimerman LI; Pimentel M; Rohde LE; Polanczyk CA
Value Health; 2010; 13(2):160-8. PubMed ID: 19725912
[TBL] [Abstract][Full Text] [Related]
20. Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium.
Van Brabandt H; Neyt M
Europace; 2009 Dec; 11(12):1571-3. PubMed ID: 19819879
[No Abstract] [Full Text] [Related]
[Next] [New Search]
